Medicine · 2025
Comparative evaluation of lung ultrasound versus chest X-ray for pneumothorax assessment post-invasive intrathoracic procedures: A case-costing evaluation.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Winberg Carter, Prager Ross, Kim Chong Sung, Meyer Matthew, Arntfield Robert
Аннотация
BACKGROUND: Persistently increasing healthcare spending, paired with growing healthcare demand, highlights the need to identify mechanisms for cost savings. Chest radiography (CXR) is commonly performed following intrathoracic procedures to rule out pneumothorax (PTX) even if the clinical pretest probability is low. However, lung ultrasound (LUS) is known to have superior sensitivity, possibly representing a promising cost-saving tool. In response, we conducted an economic analysis comparing LUS and CXR to exclude PTX after invasive intrathoracic procedures.
METHODS: A retrospective review of the radiology case-costing center was performed at an academic cardiothoracic surgical institution to identify the activity and cost of CXRs performed to rule out PTX following intrathoracic procedures. This cost was then compared to the theoretical cost of LUS.
RESULTS: CXRs performed to rule out iatrogenic PTX were common with 22,274 radiographs completed and were economically burdensome, with an associated cost of $1.4 million. Portable CXR cost $75.46 per test, while CXR posteroanterior/lateral costs $41.64. Comparatively, LUS cost $38.38. Implementation would lead to cost savings of $559,537.10 or $41.58, on average, per patient.
CONCLUSION: Given the superiority of LUS in terms of sensitivity and accuracy for PTX diagnosis, these findings underscore the compelling rationale for its broader integration into clinical practice.
METHODS: A retrospective review of the radiology case-costing center was performed at an academic cardiothoracic surgical institution to identify the activity and cost of CXRs performed to rule out PTX following intrathoracic procedures. This cost was then compared to the theoretical cost of LUS.
RESULTS: CXRs performed to rule out iatrogenic PTX were common with 22,274 radiographs completed and were economically burdensome, with an associated cost of $1.4 million. Portable CXR cost $75.46 per test, while CXR posteroanterior/lateral costs $41.64. Comparatively, LUS cost $38.38. Implementation would lead to cost savings of $559,537.10 or $41.58, on average, per patient.
CONCLUSION: Given the superiority of LUS in terms of sensitivity and accuracy for PTX diagnosis, these findings underscore the compelling rationale for its broader integration into clinical practice.